InsiderTrades.com logo

TENX Insider Trading

Insider Ownership Percentage: 3.14%
Insider Buying (Last 12 Months): $78,173.47
Insider Selling (Last 12 Months): $0.00

Tenax Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Tenax Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Tenax Therapeutics Share Price & Price History

Current Price: $9.35
Price Change: ▲ Price Increase of +0.16 (1.74%)
As of 12/4/2025 05:00 PM ET

This chart shows the closing price history over time for TENX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Tenax Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/20/2025Christopher Thomas GiordanoCEOBuy538$7.59$4,083.422,605View SEC Filing Icon  
11/19/2025Christopher Thomas GiordanoCEOBuy455$7.51$3,417.052,067View SEC Filing Icon  
11/18/2025Christopher Thomas GiordanoCEOBuy1,612$7.75$12,493.001,612View SEC Filing Icon  
11/17/2025Thomas McgauleyCFOBuy2,000$7.34$14,680.002,000View SEC Filing Icon  
11/17/2025Thomas McgauleyCFOBuy6,000$7.25$43,500.005,000View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Tenax Therapeutics (NASDAQ:TENX)

1.67% of Tenax Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at TENX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Tenax Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/17/2025Woodline Partners LP88,211$0.67M0.0%N/A1.933%Search for SEC Filing on Google Icon
11/17/2025Millennium Management LLC313,712$2.39M0.0%+34.2%6.875%Search for SEC Filing on Google Icon
11/17/2025Citadel Advisors LLC43,253$0.33M0.0%+318.1%0.948%Search for SEC Filing on Google Icon
11/17/2025Boothbay Fund Management LLC352,206$2.68M0.0%N/A7.719%Search for SEC Filing on Google Icon
11/14/2025Virtu Financial LLC12,119$92K0.0%N/A0.266%Search for SEC Filing on Google Icon
11/14/2025ADAR1 Capital Management LLC53,428$0.41M0.0%-65.7%1.171%Search for SEC Filing on Google Icon
5/16/2025ADAR1 Capital Management LLC68,741$0.45M0.1%+98.1%1.657%Search for SEC Filing on Google Icon
2/17/2025Vestal Point Capital LP55,189$0.34M0.0%-33.8%1.618%Search for SEC Filing on Google Icon
2/17/2025Two Sigma Investments LP13,521$84K0.0%N/A0.397%Search for SEC Filing on Google Icon
2/17/2025Millennium Management LLC26,809$0.17M0.0%N/A0.786%Search for SEC Filing on Google Icon
2/17/2025Janus Henderson Group PLC166,666$1.03M0.0%N/A4.888%Search for SEC Filing on Google Icon
2/13/2025ADAR1 Capital Management LLC34,693$0.22M0.0%-44.4%1.017%Search for SEC Filing on Google Icon
2/12/2025Geode Capital Management LLC24,354$0.15M0.0%+32.4%0.714%Search for SEC Filing on Google Icon
11/15/2024Sphera Funds Management LTD.29,166$0.10M0.0%N/A0.855%Search for SEC Filing on Google Icon
11/14/2024Vestal Point Capital LP83,333$0.29M0.0%N/A2.444%Search for SEC Filing on Google Icon
11/14/2024Stonepine Capital Management LLC50,000$0.17M0.1%N/A1.466%Search for SEC Filing on Google Icon
5/1/2023Virtu Financial LLC84,361$39K0.0%N/A0.377%Search for SEC Filing on Google Icon
11/14/2022Armistice Capital LLC1,965,885$0.33M0.0%+23.1%7.799%Search for SEC Filing on Google Icon
11/5/2021PNC Financial Services Group Inc.70,000$0.12M0.0%N/A0.278%Search for SEC Filing on Google Icon
8/16/2021State Street Corp136,404$0.30M0.0%N/A0.911%Search for SEC Filing on Google Icon
8/13/2021Northern Trust Corp34,671$72K0.0%+103.7%0.232%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Tenax Therapeutics logo
Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.
Read More on Tenax Therapeutics

Today's Range

Now: $9.35
Low: $8.90
High: $9.47

50 Day Range

MA: $7.66
Low: $6.68
High: $9.47

52 Week Range

Now: $9.35
Low: $4.63
High: $9.70

Volume

181,112 shs

Average Volume

99,484 shs

Market Capitalization

$58.34 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.55

Who are the company insiders with the largest holdings of Tenax Therapeutics?

Tenax Therapeutics' top insider shareholders include:
  1. Thomas Mcgauley (CFO)
  2. Christopher Thomas Giordano (CEO)
Learn More about top insider investors at Tenax Therapeutics.

Who are the major institutional investors of Tenax Therapeutics?

Tenax Therapeutics' top institutional investors include:
  1. Boothbay Fund Management LLC — 7.72%
  2. Millennium Management LLC — 6.88%
  3. Woodline Partners LP — 1.93%
  4. ADAR1 Capital Management LLC — 1.17%
  5. Citadel Advisors LLC — 0.95%
  6. Virtu Financial LLC — 0.27%
Learn More about top institutional investors of Tenax Therapeutics stock.

Which institutional investors are selling Tenax Therapeutics stock?

In the last quarter, TENX stock was sold by these institutional investors:
  1. ADAR1 Capital Management LLC

Which institutional investors are buying Tenax Therapeutics stock?

Within the previous quarter, TENX stock was bought by institutional investors including:
  1. Boothbay Fund Management LLC
  2. Woodline Partners LP
  3. Millennium Management LLC
  4. Citadel Advisors LLC
  5. Virtu Financial LLC
In the last year, these company insiders have bought Tenax Therapeutics stock:
  1. Thomas Mcgauley (CFO)
  2. Christopher Thomas Giordano (CEO)
Learn More investors buying Tenax Therapeutics stock.